Stock listing

Frankfurt:F3Y Microba Life Sciences Limited Aktie

German listing (Frankfurt) of Microba Life Sciences Limited · home listing ASX:MAP

Follow Microba Life Sciences Limited into a list and get an email when it puts out news.

Share price · FWB:F3Y

€0.018 EUR +0.001 (+6.1%)

Close on Nov 12, 2026

This year -50.0% · daily closes, Dec 1, 2025 – Nov 6, 2026, adjusted for splits
Day range
€0.018 – €0.018 EURNov 12, 2026
Market cap
€12.55M EURAt the close on Nov 12, 2026 · price × 717.1M shares outstanding
Traded on an average day
€5 EURMedian day 0 shares · 61 days with no trades · last 3 months, Aug 12, 2026 – Nov 6, 2026
Microba Life Sciences Limited logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
ASX:MAP · Home$0.036 AUD0.000 (0.0%)—$0.036$0.036$0.036$0.036Close on Nov 19, 2026
Frankfurt:F3Y€0.018 EUR+0.001 (+6.1%)—€0.018€0.018€0.018€0.017Close on Nov 12, 2026

Daily closes

Last 3 months, Aug 12, 2026 – Nov 6, 2026 · FWB:F3Y · EUR, adjusted for splits

DayCloseChange%OpenHighLowVolume
€0.0180.0000.0%€0.018€0.018€0.0180
€0.0180.0000.0%€0.018€0.018€0.0180
€0.0180.0000.0%€0.018€0.018€0.0180
€0.018+0.001+5.9%€0.018€0.018€0.0180
€0.017+0.001+6.3%€0.017€0.017€0.0170
€0.016-0.002-11.1%€0.017€0.018€0.0160
€0.0180.0000.0%€0.018€0.018€0.0180
€0.0180.0000.0%€0.018€0.018€0.0180
€0.0180.0000.0%€0.018€0.018€0.0180
€0.0180.0000.0%€0.018€0.019€0.0180
€0.018-0.001-5.3%€0.018€0.018€0.0180
€0.019-0.001-5.0%€0.019€0.019€0.0190
€0.020-0.003-13.0%€0.020€0.020€0.0200
€0.0230.0000.0%€0.023€0.023€0.0230
€0.023+0.002+9.5%€0.023€0.023€0.0230
€0.021+0.001+5.0%€0.021€0.021€0.0210
€0.020-0.005-20.0%€0.020€0.020€0.0200
€0.025-0.001-3.8%€0.025€0.025€0.0250
€0.026+0.003+13.0%€0.026€0.026€0.0260
€0.023-0.004-14.8%€0.023€0.023€0.0230
€0.027+0.001+3.8%€0.026€0.027€0.0260
€0.0260.0000.0%€0.026€0.026€0.0260
€0.026+0.001+4.0%€0.026€0.026€0.0260
€0.0250.0000.0%€0.025€0.025€0.0250
€0.0250.0000.0%€0.025€0.025€0.0250
€0.0250.0000.0%€0.025€0.026€0.0250
€0.0250.0000.0%€0.025€0.025€0.0250
€0.0250.0000.0%€0.025€0.025€0.0250
€0.0250.0000.0%€0.025€0.025€0.0250
€0.025-0.002-7.4%€0.025€0.026€0.0250
€0.027+0.001+3.8%€0.026€0.037€0.0264,800
€0.0260.0000.0%€0.026€0.026€0.0260
€0.026-0.001-3.7%€0.026€0.026€0.0260
€0.027-0.009-25.0%€0.027€0.027€0.0270
€0.036+0.011+44.0%€0.026€0.036€0.0264,800
€0.025-0.003-10.7%€0.025€0.025€0.0250
€0.0280.0000.0%€0.028€0.028€0.0280
€0.0280.0000.0%€0.028€0.028€0.0280
€0.028-0.001-3.4%€0.028€0.028€0.0280
€0.0290.0000.0%€0.029€0.029€0.0290
€0.0290.0000.0%€0.029€0.029€0.0290
€0.029-0.001-3.3%€0.029€0.029€0.0290
€0.0300.0000.0%€0.030€0.030€0.0300
€0.0300.0000.0%€0.030€0.030€0.0300
€0.030+0.001+3.4%€0.030€0.030€0.0300
€0.0290.0000.0%€0.029€0.029€0.0290
€0.0290.0000.0%€0.029€0.029€0.0290
€0.0290.0000.0%€0.029€0.029€0.0290
€0.029+0.001+3.6%€0.029€0.029€0.0290
€0.028-0.001-3.4%€0.028€0.028€0.0280
€0.0290.0000.0%€0.029€0.029€0.0290
€0.0290.0000.0%€0.029€0.029€0.0290
€0.0290.0000.0%€0.029€0.029€0.0290
€0.0290.0000.0%€0.029€0.029€0.0290
€0.029-0.001-3.3%€0.029€0.029€0.0290
€0.030+0.001+3.4%€0.030€0.030€0.0300
€0.029-0.001-3.3%€0.029€0.029€0.0290
€0.030-0.001-3.2%€0.030€0.030€0.0300
€0.031+0.003+10.7%€0.031€0.031€0.0310
€0.028+0.003+12.0%€0.028€0.028€0.0280
€0.0250.0000.0%€0.025€0.025€0.0250
€0.0250.0000.0%€0.025€0.025€0.0250
€0.0250.0000.0%€0.025€0.025€0.0250
Ticker
Frankfurt:F3Y
Asset type
Stock
Sector
Health care
Industry
Diagnostics & research services
Exchange
Frankfurt
Currency
EUR

What changed lately

Latest news

All Microba Life Sciences Limited news

Microba Life Sciences Limited on 6ix

Sector
Health care
Industry
Diagnostics & research services
News releases
48 in the last 12 months · 122 in all · newest Nov 19, 2026 · oldest 2022
Calls
10 calls with a replay · 10 with a transcript · latest Jul 22, 2025
Decks
43 decks · latest Jul 16, 2026

Where Microba Life Sciences Limited is listed

ListingExchangeCountryCurrency
ASX:MAP · Home listingASXAustraliaAUD
Frankfurt:F3Y · This pageFrankfurtGermanyEUR

Cash and shares

Jun 2026 deck · Microba Life Sciences — Investor Presentation (June 2026)

Cash
$7.28 million

The slide these figures come from

Valuation

EV/sales 1.6× against a median of 2.9×: 3rd lowest of 9 Diagnostics & research services companies shown. Statements: Year to Dec 31, 2025 · balance Jun 30, 2026 · price Nov 19, 2026

Enterprise value
$22.90M AUD
P/E
Loss
EV/sales
1.6×
EV/EBITDA
Negative EBITDA
Price/book
1.1×
Gross margin
−79.5%
Operating margin
−137.6%
Net margin
−140.4%
Debt to equity
0.2×
Beta
No index for this market yet

Diagnostics & research services: the 10 companies nearest in size, of 302 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
Microba Life Sciences Limited · ASX:MAPUS$17.70MUS$15.16Mn/a1.6×n/a1.1×−140.4%0.2×n/a
TFBS Bioscience, Inc. · TPEX:6939US$19.81MUS$7.83Mn/a1.3×n/a0.6×−38.6%0.0×n/a
SANIGEN Co., Ltd. · KRX:188260US$19.66MUS$10.06Mn/a2.2×n/a2.3×−82.6%0.1×n/a
NanoRepro AG · XETR:NN6US$19.45MUS$11.45Mn/an/an/a0.5×n/a0.0×n/a
Urteste S.A. · GPW:URTUS$19.24MUS$19.10Mn/a3,525×n/a3.5×n/a0.0×n/a
Genematrix Inc. · KRX:109820US$19.06MUS$6.80Mn/a0.8×31.7×1.4×−1.7%0.0×n/a
Oxford BioDynamics PLC · LSE:OBDUS$18.46MUS$20.77Mn/a14.5×n/a4.3×n/a1.3×n/a
RTA Laboratuvarlari Biyolojik Urunler Ilac ve Makina Sanayi Ticaret A.S. · BIST:RTALBUS$18.41MUS$16.94M1.1×3.6×61.6×0.3×367.8%0.0×n/a
Nexsen Limited · ASX:NXNUS$18.05MUS$15.08Mn/an/an/a4.8×n/a0.0×n/a
Genedrive PLC · LSE:GDRUS$17.85MUS$18.00Mn/a18.0×n/an/a−684.7%n/an/a
PlexBio Co., Ltd. · TPEX:6572US$15.79MUS$7.19Mn/a1.9×n/a1.8×−49.1%0.0×n/a
Median of the othersUS$18.76MUS$13.26M1.1×2.9×46.7×1.8×−43.9%0.0×

Forecasts

Analysts' consensus from EODHD, read Nov 10, 2026. Not 6ix's view and not investment advice.

Price target
0.082 AUD · Analysts' mean
EPS, year to Jun 2027
-0.018 · 1 analyst
Revenue, year to Jun 2027
15.36M · 1 analyst

Team and board

Officers

OfficerRole
Luke ReidChief Executive Officer
James HeathChief Financial Officer and Company Secretary
Alaster Stockwell-JonesManaging Director (UK)
Associate Professor Lutz KrauseChief Scientific Officer
David WoodChief Technology Officer
Keith ByrneHead of Test Operations

Board

DirectorRole
Ian Frazer ACDeputy Chairman of the Board, Chair of Medical Advisory Board
Pasquale RombolaChairman of the Board

Events

Results days

QuarterResultsShare move
Quarter to Mar 31, 2026Apr 23, 2026+1.4%
Q4 2025Mar 4, 2026+2.5%
Quarter to Sep 30, 2025Oct 27, 2025−4.9%
Q2 2025Aug 26, 2025−2.1%
Q1 2025Apr 17, 2025+2.8%
Q4 2024Feb 25, 2025+6.5%
Q3 2024Oct 28, 20240.0%
Q2 2024Aug 28, 2024−10.5%
Q1 2024Apr 22, 2024−8.1%
Q4 2023Feb 27, 2024+2.8%
All 17 quarters
QuarterResultsShare move
Q3 2023Nov 5, 2023−2.2%
Q2 2023Aug 29, 2023+2.9%
Q1 2023Apr 19, 2023+4.7%
Q4 2022Feb 22, 2023+1.3%
Q3 2022Nov 30, 2022−1.5%
Q2 2022Aug 25, 2022+5.0%
Q1 2022Apr 1, 2022

Open Events

Decks

DeckKindSlidesDate
Investor Presentation (July 2026)Investor deck25 slidesJul 16, 2026
Investor Presentation (June 2026)Investor deck33 slidesJun 12, 2026
Investor Presentation (April 2026)Investor deck25 slidesApr 30, 2026
Investor Presentation (January 2026)Investor deck60 slidesJan 29, 2026
Investor Presentation (October 2025)Investor deck54 slidesOct 28, 2025
Investor Presentation (July 2025)Investor deck57 slidesJul 22, 2025
Q4 2025 Earnings PresentationEarnings56 slidesJul 22, 2025
Investor Presentation (June 2025)Investor deck57 slidesJun 23, 2025
Investor Presentation (April 2025)Investor deck49 slidesApr 30, 2025
Q3 2025 Earnings PresentationEarnings48 slidesApr 29, 2025
All 43 decks
DeckKindSlidesDate
HealthInvest 2025 Investor ConferenceConference31 slidesApr 2, 2025
Investor Presentation (March 2025)Investor deck57 slidesMar 20, 2025
Investor Presentation (January 2025)Investor deck40 slidesJan 29, 2025
Q2 FY25 Earnings PresentationEarnings39 slidesJan 28, 2025
Shareholder Meeting (November 2024)Shareholder meeting25 slidesNov 29, 2024
Bell Potter Healthcare Conference 2024Conference25 slidesNov 19, 2024
Investor Presentation (October 2024)Investor deck41 slidesOct 29, 2024
Q1 2025 Earnings PresentationEarnings40 slidesOct 28, 2024
Investor Presentation (July 2024)Investor deck41 slidesJul 25, 2024
Q4 FY24 Earnings PresentationEarnings40 slidesJul 24, 2024
Investor Presentation (April 2024)Investor deck32 slidesApr 23, 2024
Q3 2024 Earnings PresentationEarnings31 slidesApr 22, 2024
Investor Presentation (March 2024)Investor deck30 slidesMar 13, 2024
Investor Presentation (January 2024)Investor deck32 slidesJan 30, 2024
Q2 2024 Earnings PresentationEarnings31 slidesJan 26, 2024
Shareholder Meeting (November 2023)Shareholder meeting27 slidesNov 30, 2023
Investor Presentation (November 2023)Investor deck32 slidesNov 6, 2023
Merger or Acquisition (October 2023)Merger or acquisition49 slidesOct 19, 2023
Investor Presentation (July 2023)Investor deck26 slidesJul 27, 2023
Q4 2023 Earnings PresentationEarnings25 slidesJul 26, 2023
Investor Presentation (April 2023)Investor deck26 slidesApr 20, 2023
Q3 2023 Earnings PresentationEarnings25 slidesApr 19, 2023
NWR Virtual Healthcare Investor Conference 2023Conference25 slidesMar 21, 2023
Q2 FY23 Earnings PresentationEarnings20 slidesJan 31, 2023
Q2 2023 Earnings PresentationEarnings19 slidesJan 28, 2023
Investor Presentation (November 2022)Investor deck17 slidesNov 29, 2022
Shareholder Meeting (November 2022)Shareholder meeting18 slidesNov 25, 2022
Q1 FY23 Earnings PresentationEarnings16 slidesOct 31, 2022
11th Annual Australian Microcap Investment Conference (October 2022)Conference15 slidesOct 17, 2022
FY2022 Earnings PresentationEarnings28 slidesAug 30, 2022
Q4 FY22 Earnings PresentationEarnings26 slidesJul 20, 2022
3rd International World of Microbiome Conference 2022Conference15 slidesApr 29, 2022
Investor Presentation (April 2022)Investor deck45 slidesApr 6, 2022

Open Decks

Financings

RaiseDateIn US dollars
Private placement of fully paid ordinary shares
Tranche closed: A$2.02M raised · A$0.04 a share
Oct 28, 2026US$1.41M
Private placement of fully paid ordinary shares with free attaching unlisted options
Announced: about A$4M · A$0.05 a share · Warrants at A$0.0625 for 36 months · Morgans Corporate Limited +1
Dealers: Morgans Corporate Limited (co-lead), Canaccord Genuity (Australia) Limited (co-lead)
Insiders: Any shares taken up by Directors under the Placement are subject to approval at the EGM
Use of proceeds: Fund the group to cashflow break-even: core diagnostics growth in Australia and UK, new testing product, working capital and offer costs
Jun 12, 2026US$2.82M
Share purchase plan of fully paid ordinary shares with free attaching unlisted options
Announced: up to A$1M · A$0.05 a share · Warrants at A$0.0625 for 36 months
Use of proceeds: Working capital
Jun 12, 2026US$704,586

Open Financings · Read by 6ix AI from the company's releases

Financials

Annual, in AUD

Income statement

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018
Revenue14.8M15.7M12.1M5.42M4.69M3.73M2.91M1.83M
Cost of revenue26.5M8.23M6.18M12.2M2.32M9.04M6.96M4.32M
Gross profit-11.7M7.44M5.91M-6.77M2.37M-5.30M-4.05M-2.49M
Research and development417.1K2.01M10.8M9.34M5.38M1.54M163.3K
Selling, general and administrative15.5M17.0M12.2M7.81M8.57M822.0K1.98M1.10M
Operating income-20.3M-24.6M-26.8M-20.2M-16.3M-9.57M-7.41M-4.79M
Depreciation and amortization4.41M4.43M2.87M1.64M1.15M1.22M1.09M765.2K
EBITDA-15.9M-20.2M-24.0M-18.6M-15.1M-8.35M-6.32M-4.02M
Interest expense238.6K176.7K69.2K60.4K55.3K23.5K37.0K24.0K
Income before tax-22.1M-15.0M-20.0M-18.8M-11.5M-7.52M-6.66M-4.72M
Income tax-1.37M-106.6K-51.3K-6.09M9.23K1-6.52K13.0K
Net income-20.7M-14.9M-19.9M-12.7M-11.5M-7.52M-6.65M-4.73M
Earnings per share, basic-0.03-0.03-0.05-0.04-0.04-0.03-0.02-0.02

Balance sheet

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018
Cash and equivalents7.95M11.7M20.9M32.0M30.6M13.0M6.90M11.0M
Short-term investments138.6K204.4K204.4K204.4K50.3K
Receivables3.21M4.11M8.10M7.24M3.42M1.65M622.8K162.3K
Inventory2.22M1.94M2.24M644.4K360.0K513.3K340.8K169.6K
Current assets13.9M19.0M32.2M41.5M35.8M16.2M8.11M11.5M
Property, plant and equipment3.87M3.91M2.58M2.81M1.20M1.63M1.60M
Goodwill9.20M10.0M8.45M
Total assets39.8M47.4M58.0M47.0M39.5M18.5M10.8M14.0M
Accounts payable2.64M2.35M3.70M2.98M813.2K353.5K392.3K267.0K
Current liabilities11.2M10.2M12.4M7.82M5.26M3.35M2.84M1.15M
Long-term debt364.5K468.7K00135.9K277.2K
Total debt4.11M3.23M1.58M1.14M1.33M269.0K563.6K406.4K
Total liabilities15.4M14.9M16.8M8.23M5.94M3.55M3.10M1.43M
Shareholders' equity24.4M32.5M41.2M38.6M33.5M14.9M7.70M12.6M
Shares outstanding600.6M448.4M409.9M333.0M290.7M290.7M290.7M290.7M

Cash flow

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018
Cash from operations-12.4M-12.0M-15.6M-12.4M-10.4M-7.18M-4.32M-3.62M
Capital spending-240.3K-2.90M-4.38M-3.04M-1.87M-672.5K-856.2K-836.1K
Free cash flow-12.6M-14.9M-19.9M-15.4M-1.87M-7.85M-5.18M-4.46M
Cash from investing-3.80M-2.83M-13.9M-3.00M-1.73M-522.5K-856.2K-833.7K
Cash from financing12.8M5.58M18.4M16.7M29.2M13.8M1.08M13.7M
Dividends paid-595.6K-425.3K
Share buybacks-714.6K-384.7K-1.26M-595.6K-1.90M15.1M1.40M10.6M
Change in cash-3.79M-9.15M-11.2M1.46M17.6M6.13M-4.10M11.0M

Open Financials

Filings

FilingDateTypeFiled with
BCAL Position on GSS-MAP MergerNov 18, 2026Acquisition or disposalASX
MAP: Proposed Merger with GSS not proceedingNov 17, 2026Acquisition or disposalASX
GSS: End of Proposed Merger with Microba Life SciencesNov 17, 2026Acquisition or disposalASX
Suspension from QuotationNov 16, 2026Trading halt or suspensionASX
TOV: GSS - Panel Receives ApplicationNov 13, 2026Other filingsASX
Trading Halt RequestNov 13, 2026Trading halt or suspensionASX
Trading HaltNov 13, 2026Trading halt or suspensionASX
Pause in TradingNov 12, 2026Trading halt or suspensionASX
Cleansing NoticeOct 28, 2026FinancingASX
Application for quotation of securities - MAPOct 27, 2026FinancingASX
All 120 filings
FilingDateTypeFiled with
Letter to Shareholders, Notice of AGM & Proxy FormOct 27, 2026Meeting noticeASX
Final Director's Interest Notice - Ian FrazerOct 26, 2026Ownership change noticeASX
Final Director's Interest Notice - Gene TysonOct 26, 2026Ownership change noticeASX
Notification of cessation of securities - MAPOct 22, 2026FinancingASX
Update on Commercial Terms for Proposed Merger with MAPOct 20, 2026Acquisition or disposalASX
Proposed issue of securities - MAPOct 19, 2026FinancingASX
Proposed issue of securities - MAPOct 19, 2026FinancingASX
Q1 FY27 Quarterly Activities Report & Appendix 4COct 19, 2026Quarterly reportASX
Q1 FY27 Quarterly Activities Report & Appendix 4COct 19, 2026Quarterly reportASX
Microba secures $2m placement and increases cost reductionsOct 19, 2026FinancingASX
Microba secures $2m placement and increases cost reductionsOct 19, 2026FinancingASX
Date of AGM and closing date for Director NominationsOct 13, 2026Meeting noticeASX
Notification of cessation of securities - MAPOct 13, 2026FinancingASX
Microba launches GI Navigator in Australia and the UKOct 6, 2026Operations updateASX
Change in substantial holdingSep 30, 2026Ownership change noticeASX
Appointment of Interim Chief Executive OfficerSep 24, 2026Management or board changeASX
GSS and MAP agree to Commercial Terms for MergerSep 21, 2026Acquisition or disposalASX
2026 Annual Report & Appendix 4EAug 30, 2026Annual reportASX
2026 Appendix 4GAug 30, 2026Other filingsASX
2026 Corporate Governance StatementAug 30, 2026Other filingsASX
Genetic Signatures and Microba in Merger DiscussionsAug 25, 2026Acquisition or disposalASX
Change of Director's Interest Notice - Pasquale RombolaJul 31, 2026Ownership change noticeASX
Change of Director's Interest Notice - Prof Ian FrazerJul 31, 2026Ownership change noticeASX
Cleansing NoticeJul 29, 2026FinancingASX
Notification regarding unquoted securities - MAPJul 28, 2026Other filingsASX
Notification regarding unquoted securities - MAPJul 28, 2026Other filingsASX
Application for quotation of securities - MAPJul 28, 2026FinancingASX
Notification regarding unquoted securities - MAPJul 28, 2026Other filingsASX
Application for quotation of securities - MAPJul 28, 2026FinancingASX
Completion of Share Purchase PlanJul 27, 2026FinancingASX
Q4 FY26 Quarterly Investor Presentation & WebinarJul 15, 2026Quarterly reportASX
Investor presentation - path to cashflow breakevenJun 11, 2026Other filingsASX
Pause in TradingJun 2, 2026Trading halt or suspensionASX
Q3 FY26 Quarterly Investor Presentation & WebinarApr 29, 2026Other filingsASX
Appendix 4D & FY26 Interim ReportFeb 25, 2026Interim reportASX
Q2 FY26 Quarterly Investor Presentation & WebinarJan 28, 2026Other filingsASX
Q2 FY26 Quarterly Activities Report & Appendix 4CJan 28, 2026Quarterly reportASX
Microba receives $3 million R&D Tax Incentive RefundDec 2, 2025ResultsASX
Q1 FY26 Quarterly Investor Presentation & WebinarOct 27, 2025Quarterly reportASX
Q1 FY26 Quarterly Activities Report & Appendix 4COct 27, 2025Quarterly reportASX
2025 Annual Report & Appendix 4EAug 26, 2025Annual reportASX
Q4 FY25 Quarterly Investor Presentation & WebinarJul 21, 2025Quarterly reportASX
Q4 FY25 Quarterly Activities Report & Appendix 4CJul 21, 2025Quarterly reportASX
Disclosure Document - ProspectusJun 27, 2025Offer documentASX
Reinstatement to QuotationJun 23, 2025Trading halt or suspensionASX
Strategic Investment & Equity Raise PresentationJun 23, 2025Other filingsASX
Microba secures $14.5 million to drive clinical adoptionJun 23, 2025FinancingASX
Suspension from QuotationJun 23, 2025Trading halt or suspensionASX
Trading HaltJun 18, 2025Trading halt or suspensionASX
MetaPanel Pathogen Study Delivers Breakthrough ResultsMay 20, 2025ResultsASX
Landmark GI Study Results from over 4,600 patientsMay 13, 2025ResultsASX
Q3 FY25 Quarterly Investor Presentation & WebinarApr 29, 2025Quarterly reportASX
Q3 FY25 Quarterly Activities Report & Appendix 4CApr 29, 2025Quarterly reportASX
Appendix 4D & FY25 Interim ReportFeb 25, 2025Interim reportASX
Q2 FY25 Quarterly Investor Presentation & WebinarJan 28, 2025Quarterly reportASX
Q2 FY25 Quarterly Activities Report & Appendix 4CJan 28, 2025Quarterly reportASX
Trading UpdateNov 28, 2024Operations updateASX
Microba receives $6 million R&D Tax Incentive RefundNov 17, 2024Other filingsASX
Q1 FY25 Quarterly Activities Report & Appendix 4COct 28, 2024Quarterly reportASX
Q1 FY25 Quarterly Investor PresentationOct 28, 2024Other filingsASX
2024 Annual Report & Appendix 4EAug 28, 2024Annual reportASX
Q4 FY24 Quarterly Investor Presentation & WebinarJul 24, 2024Quarterly reportASX
Q4 FY24 Quarterly Activities Report & Appendix 4CJul 24, 2024Quarterly reportASX
Completion of Autoimmune Program with Ginkgo BioworksJun 27, 2024Operations updateASX
Q3 FY24 Quarterly Investor PresentationApr 22, 2024Quarterly reportASX
Q3 FY24 Quarterly Activities Report & Appendix 4CApr 22, 2024Quarterly reportASX
Microba receives $6.08 million R&D Tax Incentive RefundApr 10, 2024ResultsASX
MetaPanel Launch Investor PresentationMar 12, 2024Other filingsASX
MetaPanel Diagnostic Test Launched with Sonic HealthcareMar 12, 2024Other filingsASX
Appendix 4D & FY24 Interim ReportFeb 27, 2024Interim reportASX
Q2 FY24 Quarterly Investor PresentationJan 29, 2024Quarterly reportASX
Q2 FY24 Quarterly Activities Report & Appendix 4CJan 29, 2024Quarterly reportASX
Successful IBD Phase I Clinical TrialDec 6, 2023Other filingsASX
Research Agreement Executed with IFF for Allergy ProgramDec 3, 2023Other filingsASX
Autoimmune Stage 1 Screening Complete with Gingko BioworksNov 27, 2023Operations updateASX
Results of Retail Entitlement OfferNov 19, 2023ResultsASX
Fully Underwritten A$20 million Entitlement OfferOct 22, 2023FinancingASX
Invivo Clinical Acquisition and Capital Raising PresentationOct 18, 2023FinancingASX
Microba to acquire UK microbiome leader Invivo ClinicalOct 18, 2023Acquisition or disposalASX
Q1 FY24 Quarterly Activities Report & Appendix 4COct 18, 2023Quarterly reportASX
Appendix 4E & Annual ReportAug 29, 2023Annual reportASX
Q4 FY23 Quarterly Investor PresentationJul 26, 2023Other filingsASX
Q4 FY23 Quarterly Activities Report & Appendix 4CJul 26, 2023Quarterly reportASX
First Distribution Agreement Executed with Sonic HealthcareJul 4, 2023Other filingsASX
Microba Commences Phase I Clinical Trial for IBD TherapeuticJun 27, 2023Other filingsASX
MRFF Grant Awarded to QUT, In Collaboration With MicrobaJun 27, 2023Other filingsASX
Microba receives two AusIndustry Advanced Overseas FindingsJun 14, 2023Other filingsASX
Q3 FY23 Quarterly Investor PresentationApr 19, 2023Other filingsASX
Q3 FY23 Quarterly Activities Report & Appendix 4CApr 19, 2023Quarterly reportASX
SYNLAB Contracts Signed in Poland, Hungary, Romania, CroatiaApr 12, 2023Other filingsASX
Microba Receives Ethics Approval for Phase 1 Clinical TrialMar 29, 2023Other filingsASX
SYNLAB Agreements Signed in Turkiye and Czech RepublicMar 1, 2023Other filingsASX
Microba Launches Next Generation Healthcare TestingFeb 27, 2023Other filingsASX
H1 FY23 Interim ReportFeb 22, 2023Interim reportASX
US Distribution Agreement Signed with Luminary HealthFeb 6, 2023Other filingsASX
Positive first animal data for Cancer ProgramJan 31, 2023Other filingsASX
Q2 FY23 Quarterly Activities Report & Appendix 4CJan 29, 2023Quarterly reportASX
SYNLAB Agreements Signed in Italy and PortugalDec 7, 2022Other filingsASX
Sonic Investment & Partnership Investor PresentationNov 28, 2022Other filingsASX
Sonic Acquires 19.9% Microba Stake and Enters PartnershipNov 28, 2022Acquisition or disposalASX
Microba receives $2.62m R&D Tax Incentive refundOct 31, 2022Other filingsASX
Q1 FY23 Quarterly Activities Report & Appendix 4COct 26, 2022Quarterly reportASX
Microba, SYNLAB Extend & Expand DistributionOct 19, 2022Other filingsASX
Therapeutic Program AdvancementAug 30, 2022Other filingsASX
Investor Presentation - FY22 Update Annual ResultsAug 29, 2022Other filingsASX
Q4 FY22 Quarterly Activities Report & Appendix 4CJul 19, 2022Quarterly reportASX
G42 Healthcare Partnership Commences OperationJun 27, 2022Other filingsASX
Microba & Ginkgo Commence Therapeutics ProgramJun 7, 2022Other filingsASX
Partnership signed with nib-backed Midnight HealthMay 25, 2022Other filingsASX
Microba Accelerates Cancer ProgramMay 5, 2022Other filingsASX

Open Filings

Cap table

Built by 6ix from Microba Life Sciences Limited’s releases · as of Oct 28, 2026

Common shares
742,742,274
Fully diluted
742,742,274

Fully diluted

LineSharesAs of
Common shares742,742,274Oct 28, 2026

Share count over time

CountShares
Oct 28, 2026742,742,274

Open Cap table

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
Alaster Stockwell-JonesManaging Director (UK) · Since at least Nov 5, 2026
Associate Professor Lutz KrauseChief Scientific Officer · Since at least Nov 5, 2026
David WoodChief Technology Officer · Since at least Nov 5, 2026
Ian Frazer ACDeputy Chairman of the Board, Chair of Medical Advisory Board · Since at least Nov 5, 2026
James HeathChief Financial Officer and Company Secretary · Since at least Nov 5, 2026
Keith ByrneHead of Test Operations · Since at least Nov 5, 2026
Luke ReidChief Executive Officer · Since at least Nov 5, 2026
Pasquale RombolaChairman of the Board · Since at least Nov 5, 2026

Open People

Log in to ask 6ix AI your own questions about Microba Life Sciences Limited.